jimki

Antibiotics as Pretreatment for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials and Prospective Cohort Studies

Authors

  • Jihan Muthmainah

  • Altisa Liviadianti

  • Fayyaza Khairunnisa

  • Inas Qonita

  • Anisa Nuraisa Djausal

  • Tri Umiana Sholeha

  • Lydia Theresia

  • Zahara Nurfatihah Z

DOI:
https://doi.org/10.53366/jimki.v13i1.1165
Keywords:
Array, Array, Array, Array
Abstract

Introduction: Inflammatory Bowel Disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract associated with gut microbiota dysbiosis. Fecal Microbiota Transplantation (FMT) has been developed to restore microbial balance; however, its effectiveness remains variable due to differences in pre-treatment approaches. This systematic review aimed to evaluate the effectiveness and safety of antibiotic administration prior to FMT in patients with IBD. Method: This systematic review was conducted in accordance with the PRISMA 2020 guidelines. Literature searches were performed in PubMed/MEDLINE and ScienceDirect through May 2026. Eligible studies included randomized controlled trials and prospective cohort studies evaluating antibiotic use before FMT in patients with IBD. The primary outcomes were clinical response and clinical remission, while secondary outcomes included endoscopic remission, donor microbiota engraftment, inflammatory biomarkers, and treatment safety. Results: Antibiotic administration prior to FMT may support therapeutic efficacy by reducing dysbiosis and facilitating donor microbiota colonization. Most studies reported improvements in clinical response and remission, microbial diversity, donor engraftment, and gut microbial composition, although the magnitude of benefit varied across studies. Several studies also reported changes in inflammatory and metabolic biomarkers. Conclusion: Antibiotic pre-treatment before FMT may improve therapeutic outcomes in patients with IBD by enhancing clinical response and remission, improving gut microbial composition, and promoting successful donor engraftment. Further studies with standardized protocols are needed to determine the most effective antibiotic regimen, dosage, and treatment duration.

References

Zhang Y, Xue G, Wang F, Zhang J, Xu L, Yu C. The impact of antibiotic exposure on antibiotic resistance gene dynamics in the gut microbiota of inflammatory bowel disease patients. Front Microbiol. 2024;15:1382332.

2. Park SH. Update on the epidemiology of inflammatory bowel disease in Asia: where are we now? Intest Res. 2022;20(2):159–164. doi:10.5217/ir.2021.00115.

3. Santana PT, Rosas SLB, Ribeiro BE, Marinho Y, de Souza HSP. Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets. Int J Mol Sci. 2022;23(7):3464. doi:10.3390/ijms23073464.

4. Singh P, Alm EJ, Kelley JM, Cheng V, Smith M, Kassam Z, Nee J, Iturrino J, Lembo A. Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D. Gut Microbes. 2022;14(1):2020067. doi:10.1080/19490976.2021.2020067.

5. Freitag TL, Hartikainen A, Jouhten H, Sahl C, Meri S, Anttila VJ, Mattila E, Arkkila P, Jalanka J, Satokari R. Minor Effect of Antibiotic Pre-treatment on the Engraftment of Donor Microbiota in Fecal Transplantation in Mice. Front Microbiol. 2019;10:2685. doi:10.3389/fmicb.2019.02685.

6. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar;372:n71.

7. Haifer C, Paramsothy S, Kaakoush NO, Saikal A, Ghaly S, Yang T, et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2022 Feb 1;7(2):141–51.

8. Ishikawa D, Sasaki T, Osada T, Kuwahara-Arai K, Haga K, Shibuya T, Hiramatsu K, Watanabe S. Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis. Inflamm Bowel Dis. 2017;23(1):116–125. doi:10.1097/MIB.0000000000000975.

9. Okahara K, Ishikawa D, Nomura K, Ito S, Haga K, Takahashi M, et al. Matching between Donors and Ulcerative Colitis Patients Is Important for Long-Term Maintenance after Fecal Microbiota Transplantation. J Clin Med. 2020;9(6):1650. doi:10.3390/jcm9061650.

10. Kump P, Wurm P, Gröchenig HP, Wenzl H, Petritsch W, Halwachs B, et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther. 2018;47(1):67–77. doi:10.1111/apt.14387.

11. van Lingen EE, Baunwall SSMD, Lieberknecht SSC, Benech NN, Ianiro GG, Sokol HH, et al. Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease. Ther Adv Gastroenterol. 2023;16:17562848231156285 doi:10.1177/17562848231156285.

12. Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. 2023 Mar;13(3):e065186.

13. Smith BJ, Piceno Y, Zydek M, Zhang B, Syriani LA, Terdiman JP, et al. Strain-resolved analysis in a randomized trial of antibiotic pretreatment and maintenance dose delivery mode with fecal microbiota transplant for ulcerative colitis. Sci Rep. 2022;12:5517. doi:10.1038/s41598-022-09307-5.

14. Ji SK, Yan H, Jiang T, Guo CY, Liu JJ, Dong SZ, et al. Preparing the Gut with Antibiotics Enhances Gut Microbiota Reprogramming Efficiency by Promoting Xenomicrobiota Colonization. Front Microbiol. 2017;8:1208.

15. Hou S, Yu J, Li Y, Zhao D, Zhang Z. Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases. Adv Sci (Weinh). 2025;12(13):e2413197. doi:10.1002/advs.202413197.

16. Ishikawa D, Watanabe H, Nomura K, Zhang X, Maruyama T, Odakura R, et al. Patient–donor similarity and donor-derived species contribute to the outcome of fecal microbiota transplantation for ulcerative colitis. J Crohn’s Colitis. 2025;19(4):jjaf054.

17. Ishikawa D, Sasaki T, Takahashi M, Kuwahara-Arai K, Haga K, Ito S, et al. The Microbial Composition of Bacteroidetes Species in Ulcerative Colitis Is Effectively Improved by Combination Therapy With Fecal Microbiota Transplantation and Antibiotics. Inflamm Bowel Dis. 2018 Nov;24(12):2590–8.

18. Zhang B, Magnaye KM, Stryker E, et al. Sustained mucosal colonization and fecal metabolic dysfunction by Bacteroides associates with fecal microbial transplant failure in ulcerative colitis patients. Sci Rep. 2024;14:18558. doi:10.1038/s41598-024-62463-8.

19. Zhang YJ, Bousvaros A, Docktor M, et al. Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after fecal microbiota transplant in inflammatory bowel disease. Sci Rep. 2024;14:18188. doi:10.1038/s41598-024-68619-w.

Cover Image
Downloads
Published
2026-09-08
Issue
Vol. 13 No. 1 (2026): JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Vol 13.1 (2026)
Section
Article Review
License

Copyright (c) 2026 Jihan Muthmainah, Altisa Liviadianti, Fayyaza Khairunnisa, Inas Qonita, Anisa Nuraisa Djausal, Tri Umiana Sholeha, Lydia Theresia, Zahara Nurfatihah Z

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Antibiotics as Pretreatment for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials and Prospective Cohort Studies . (2026). JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 13(1), 69-96. https://doi.org/10.53366/jimki.v13i1.1165